Cargando…
A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance
N‐methyl‐D‐aspartate ionotropic glutamatergic receptor (NMDAR) modulators, including rapastinel and ketamine, elicit rapid and sustained antidepressant responses in patients with treatment‐resistant major depressive disorder. This phase I, randomized, multicenter, placebo‐controlled, five‐period, cr...
Autores principales: | Su, Shengfang, Kay, Gary, Hochadel, Thomas, Rojo, Jonathan, Christopher Stein, J., Boinpally, Ramesh, Periclou, Antonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742651/ https://www.ncbi.nlm.nih.gov/pubmed/34423904 http://dx.doi.org/10.1111/cts.13145 |
Ejemplares similares
-
Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression
por: Yang, Bangkun, et al.
Publicado: (2016) -
Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021) -
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020) -
Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019) -
ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice
por: Shen, Mengxin, et al.
Publicado: (2022)